Overview
The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
Description
The study aims to assess long-term safety and performance of MINIject glaucoma implant up to 5 years post-implantation. Patients who received implant and were followed for 2 years in a previous study, will be invited to continue long-term follow-up from 2 to 5 years post-implantation at annual intervals. Standard ophthalmologic assessments including measurement of intraocular pressure, fundus examination, ocular imaging, assessment of any untoward ocular events etc. will be performed.
Eligibility
Inclusion Criteria:
- Patient who received a MINIject glaucoma implant within a prior clinical study
- Patient continues to have MINIject implanted at the point of enrolment
- Patient must provide written informed consent to participate
Exclusion Criteria:
- Individuals under tutorship or trusteeship
- Patient who is unwilling to return to the study visits and undergo study assessments, as required by clinical study protocol